KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors
| Autor: | María Auxiliadora Gómez-España, Javier López-González, Alberto L. Moreno-Vega, Enrique Aranda-Aguilar, Barbara Manzanares-Martin, Rafael Gonzalez-Fernandez, Beatriz Chia-Delgado, Antonio Rodríguez-Ariza, Ignacio Porras-Quintela, Cristina Morales-Estevez, Juan de la Haba-Rodriguez, Maria Jose Ortiz-Morales, Maria T. Cano-Osuna |
|---|---|
| Přispěvatelé: | [Morales-Estevez, Cristina] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Med Oncol, Cordoba, Spain, [De la Haba-Rodriguez, Juan] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Med Oncol, Cordoba, Spain, [Porras-Quintela, Ignacio] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Med Oncol, Cordoba, Spain, [Rodriguez-Ariza, Antonio] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Med Oncol, Cordoba, Spain, [Moreno-Vega, Alberto] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Med Oncol, Cordoba, Spain, [Ortiz-Morales, Maria J.] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Med Oncol, Cordoba, Spain, [Gomez-Espana, Maria A.] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Med Oncol, Cordoba, Spain, [Cano-Osuna, Maria T.] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Med Oncol, Cordoba, Spain, [Lopez-Gonzalez, Javier] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Med Oncol, Cordoba, Spain, [Chia-Delgado, Beatriz] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Med Oncol, Cordoba, Spain, [Aranda-Aguilar, Enrique] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Med Oncol, Cordoba, Spain, [De la Haba-Rodriguez, Juan] Inst Salud Carlos III, Spanish Canc Network RTICC, Madrid, Spain, [Rodriguez-Ariza, Antonio] Inst Salud Carlos III, Spanish Canc Network RTICC, Madrid, Spain, [Aranda-Aguilar, Enrique] Inst Salud Carlos III, Spanish Canc Network RTICC, Madrid, Spain, [Manzanares-Martin, Barbara] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Immunol, Cordoba, Spain, [Gonzalez-Fernandez, Rafael] Univ Cordoba, Reina Sofia Univ Hosp, IMIBIC, Dept Immunol, Cordoba, Spain |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Dependent cell cytotoxicity Colorectal-cancer medicine.drug_class Immunology KIR/HLA ligands KIR receptor Human leukocyte antigen Biology Monoclonal antibody 03 medical and health sciences 0302 clinical medicine Trastuzumab Receptors medicine Immunology and Allergy advanced cancer Chemotherapy Disease Polymorphism Genotyping Breast-cancer Original Research Antibody-dependent cell-mediated cytotoxicity Transplantation natural killer cells Cetuximab Cancer medicine.disease anti-EGFR Hla class-i 030104 developmental biology 030220 oncology & carcinogenesis solid tumor Primer (molecular biology) medicine.drug |
| Zdroj: | Frontiers in Immunology |
| DOI: | 10.3389/fimmu.2016.00561/pdf |
| Popis: | Killer-cell immunoglobulin-like receptors (KIRs) regulate the killing function of natural killer cells, which play an important role in the antibody-dependent cell-mediated cytotoxicity response exerted by therapeutic monoclonal antibodies (mAbs). However, it is unknown whether the extensive genetic variability of KIR genes and/or their human leukocyte antigen (HLA) ligands might influence the response to these treatments. This study aimed to explore whether the variability in KIR/HLA genes may be associated with the variable response observed to mAbs based anti-epidermal growth factor receptor (EGFR) therapies. Thirty-nine patients treated with anti-EGFR mAbs (trastuzumab for advanced breast cancer, or cetuximab for advanced colorectal or advanced head and neck cancer) were included in the study. All the patients had progressed to mAbs therapy and were grouped into two categories taking into account time to treatment failure (TTF ≤6 and ≥10 months). KIR genotyping (16 genetic variability) was performed in genomic DNA from peripheral blood by PCR sequence-specific primer technique, and HLA ligand typing was performed for HLA-B and -C loci by reverse polymerase chain reaction sequence-specific oligonucleotide methodology. Subjects carrying the KIR/HLA ligand combinations KIR2DS1/HLAC2C2-C1C2 and KIR3DS1/HLABw4w4-w4w6 showed longer TTF than non-carriers counterparts (14.76 vs. 3.73 months, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|